Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Lymphoma

  Free Subscription


21.10.2019

2 Am J Hematol
1 Am J Pathol
1 Am J Surg Pathol
1 Blood
1 BMC Cancer
1 Br J Haematol
1 Cancer
1 Eur J Haematol
2 Haematologica
1 Int J Cancer
1 J Am Acad Dermatol
2 J Clin Oncol
4 Leuk Lymphoma
1 Oncogene
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol


  1. Abstracts from the 2019 Lymphoma and Myeloma Congress October 23-26, 2019 New York, NY.
    Am J Hematol. 2019;94 Suppl 2:S3-S33.
    PubMed     Text format    

  2. HERRERA AF, Goy A, Mehta A, Ramchandren R, et al
    Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
    Am J Hematol. 2019 Oct 17. doi: 10.1002/ajh.25659.
    PubMed     Text format     Abstract available


    Am J Pathol

  3. TURNER SD, Inghirami G, Miranda RN, Kadin ME, et al
    Cell of Origin and Immunological Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.
    Am J Pathol. 2019 Oct 11. pii: S0002-9440(19)30753.
    PubMed     Text format     Abstract available


    Am J Surg Pathol

  4. CHEN Z, Zou Y, Liu W, Guan P, et al
    Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Am J Surg Pathol. 2019 Oct 11. doi: 10.1097/PAS.0000000000001386.
    PubMed     Text format     Abstract available


    Blood

  5. ELENITOBA-JOHNSON KSJ
    Functional profiling to improve therapy in TCL.
    Blood. 2019;133:504-506.
    PubMed     Text format    


    BMC Cancer

  6. KIM JH, Kim WS, Park C
    Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    BMC Cancer. 2019;19:936.
    PubMed     Text format     Abstract available


    Br J Haematol

  7. LAGERLOF I, Holte H, Glimelius I, Bjorkholm M, et al
    No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16232.
    PubMed     Text format     Abstract available


    Cancer

  8. EYRE TA, Collins GP, Gupta A, Coupe N, et al
    A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
    Cancer. 2019;125:99-108.
    PubMed     Text format     Abstract available


    Eur J Haematol

  9. MALENDA A, Kolkowska-Lesniak A, Pula B, Dlugosz-Danecka M, et al
    Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma.
    Eur J Haematol. 2019 Oct 13. doi: 10.1111/ejh.13337.
    PubMed     Text format     Abstract available


    Haematologica

  10. STRATI P, Ahmed MAA, Fowler N, Nastoupil LJ, et al
    Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.
    Haematologica. 2019 Oct 10. pii: haematol.2019.230649.
    PubMed     Text format     Abstract available

  11. SMITH VM, Dietz A, Henz K, Bruecher D, et al
    Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
    Haematologica. 2019 Oct 10. pii: haematol.2019.220525.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. LIU Z, Jarrett RF, Hjalgrim H, Proietti C, et al
    Evaluation of the antibody response to the EBV proteome in EBV-associated classic Hodgkin lymphoma.
    Int J Cancer. 2019 Oct 16. doi: 10.1002/ijc.32741.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  13. HEYMANN WR
    Predicting the nature of follicular mucinosis: Still a sticky situation.
    J Am Acad Dermatol. 2019;80:1524-1525.
    PubMed     Text format    


    J Clin Oncol

  14. BORCHMANN S, Cirillo M, Goergen H, Meder L, et al
    Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma.
    J Clin Oncol. 2019 Oct 17:JCO1900985. doi: 10.1200/JCO.19.00985.
    PubMed     Text format     Abstract available

  15. ARMAND P, Rodig S, Melnichenko V, Thieblemont C, et al
    Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
    J Clin Oncol. 2019 Oct 14:JCO1901389. doi: 10.1200/JCO.19.01389.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  16. BATOROV EV, Pronkina NV, Tikhonova MA, Kryuchkova IV, et al
    Increased circulating CD3(+) T cells are associated with early relapse following autologous hematopoietic stem cell transplantation in patients with classical Hodgkin lymphoma.
    Leuk Lymphoma. 2019;60:2488-2497.
    PubMed     Text format     Abstract available

  17. ZHUANG WH, Wang YP
    Analysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphoma.
    Leuk Lymphoma. 2019 Oct 15:1-7. doi: 10.1080/10428194.2019.1672053.
    PubMed     Text format     Abstract available

  18. KUMAR P, Uppal M, Xiao W, Dogan A, et al
    Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
    Leuk Lymphoma. 2019 Oct 15:1-5. doi: 10.1080/10428194.2019.1675876.
    PubMed     Text format    

  19. BAPTISTA MJ, Sole F, Polliack A, Matutes E, et al
    Report of the International Splenic Lymphoma Study Group meeting held in 2019 in Barcelona, Spain.
    Leuk Lymphoma. 2019 Oct 15:1-3. doi: 10.1080/10428194.2019.1675878.
    PubMed     Text format    


    Oncogene

  20. NAKAYAMA R, Ueno Y, Ueda K, Honda T, et al
    Latent infection with Kaposi's sarcoma-associated herpesvirus enhances retrotransposition of long interspersed element-1.
    Oncogene. 2019;38:4340-4351.
    PubMed     Text format     Abstract available


    PLoS One

  21. VAN DER MEEREN LE, Kluiver J, Rutgers B, Alsagoor Y, et al
    A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
    PLoS One. 2019;14:e0223260.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: